Phase II study of age-adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL)

Trial Profile

Phase II study of age-adjusted R-BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FIL-RBAC500
  • Most Recent Events

    • 12 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Aug 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top